IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
103.26
-0.01 (-0.01%)
At close: 4:00PM EDT

103.80 +0.54 (0.52%)
After hours: 5:55PM EDT

Stock chart is not supported by your current browser
Previous Close103.27
Open103.29
Bid103.30 x 100
Ask108.00 x 200
Day's Range102.35 - 103.96
52 Week Range94.20 - 119.30
Volume1,679,477
Avg. Volume3,034,664
Net Assets9.03B
NAV106.73
PE Ratio (TTM)3.59
Yield0.21%
YTD Return-0.03%
Beta (3y)1.40
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • What strong global growth means for US markets
    CNBC Videos8 days ago

    What strong global growth means for US markets

    Kevin Mahn, Hennion and Walsh Asset Management, and Sorin Roibu, Brandywine Global, discuss the IMF's 3 percent growth forecast and what to expect this earnings season.

  • Earnings bar too high? Experts weigh in
    CNBC Videos12 days ago

    Earnings bar too high? Experts weigh in

    Chris Zaccarelli, Independent Advisor Alliance, and Dan Wantrobski, Janney Montgomery Scott, discuss whether the market's response to bank earnings is indicative of things to come.

  • Cramer Remix: Here's how Mark Zuckerberg should respond t...
    CNBC Videoslast month

    Cramer Remix: Here's how Mark Zuckerberg should respond t...

    Jim Cramer explains why Facebook’s current approach isn’t working and how the company should proceed.

  • Cramer: These charts show 'signs of life' for biotech
    CNBC Videoslast month

    Cramer: These charts show 'signs of life' for biotech

    Jim Cramer eyes the biotechnology sector with technician Carolyn Boroden so see if the troubled stock group can bounce back anytime soon.

  • Cramer's charts show 'signs of life' for the struggling b...
    CNBC Videoslast month

    Cramer's charts show 'signs of life' for the struggling b...

    Jim Cramer eyes the biotechnology sector with technician Carolyn Boroden so see if the troubled stock group can bounce back anytime soon.

  • Stock Market Analysis 4/18/18
    Yahoo Finance Contributors7 days ago

    Stock Market Analysis 4/18/18

  • Yahoo Finance Contributors11 days ago

    Stock Market Video Analysis 4/14/19

  • Stock Market, Gold & Bitcoin Analysis 4/6/18
    Yahoo Finance Contributors18 days ago

    Stock Market, Gold & Bitcoin Analysis 4/6/18

  • Investopedia5 hours ago

    3 Charts That Suggest Biotech Stocks Are Headed Lower

    Rising levels of market volatility and subsequent selling pressure have started to take hold of the strongest performing market segments such as biotechnology. The sudden shift in sentiment now has some active traders talking about a long-term shift in trend. Traders who want to gain exposure to a broad range of biotechnology companies often look to exchange-traded products such as the iShares Nasdaq Biotechnology ETF.

  • Investopedia13 hours ago

    Why Biogen's Stock Rebound Is Good News for Biotechs

    An analysis of the technical chart of Biogen Inc. ( BIIB) shows the stock could be set to rebound by about 7%, giving shares the chance to rise back towards $282 from its price of roughly $263, a jump of about 7.5%. Biogen shares were up by roughly 1% on April 24, after the company reported better than expected first-quarter earnings per share, and revenue that was in line with estimates. Biogen's stock has been hit hard in 2018, with the stock down by nearly 30%, since late January peaking near $370 per share. Biogen shares fell to an intraday low of $251, a significant technical support level, that goes back to July of 2016.

  • Market Realist6 days ago

    No Bid Coming for Shire Reportedly

    CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier.

  • ETF Database6 days ago

    Trending: Investors Apathetic to Barclays' $1.2 Billion ETN Shutoff

    This week, investors were preoccupied with Russia, as the country’s equities fell dramatically after the relations with countries in the West, including the U.S., deteriorated. First in the list, however, is Barclays Capital, as the asset management arm of the British bank said it would shut down a host of exchange-traded notes (ETNs). Russia is second in the list followed by crude oil, which has been on a tear lately thanks to dropping stockpiles in the U.S. Leveraged ETFs and biotechnology stocks close the list. Check our previous trends edition at Trending: Soybean Prices Whipsaw on Trade War Fears.

  • Why These Small Cap Biotech ETFs are Soaring
    Zacks7 days ago

    Why These Small Cap Biotech ETFs are Soaring

    These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.

  • Investopedia13 days ago

    3 Biotech Stocks Analysts Have Been Too Bullish On

    Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.

  • InvestorPlace17 days ago

    Exact Sciences Corporation Could Break Out Despite Steep Drop in Biotech

    EXAS stock is down almost 29% in the same period. Exact is a promising laboratory and research firm in the business of screening patients for colon cancer. Patient compliance for the screening test is at a modest 65% .

  • Investopedia19 days ago

    Biotech's Exact Sciences Seen Plunging 25%

    With shares around $38.75, options traders are betting the stock falls by another 25% by Dec. 31.

  • Market Realist19 days ago

    Can You Avoid the Tariff Trouble in the S&P 500?

    The market did kind of decide to shrug off tariffs and hope they were more of a bargaining chip. If we shrug off the tariffs today, that would be a big win for the market. When they move up, the market worries about choking off growth.

  • Barrons.com21 days ago

    Biotech Sector Could See New Life

    Biotech hasn't had a great start to the year: The iShares Nasdaq Biotechnology ETF (IBB) is down 4.4% year-to-date, and while the SPDR S&P Biotech ETF (XBI) has been the better performer of the two, as Barron's predicted, it's fallen 1.4%.  However, Oppenheimer's Leah Rush Cann thinks that the group could be poised for a positive reversal, based on valuation--which she believes looks attractive--along with earnings growth expectations. Cann writes that she has long held that the biggest catalyst for biotech stocks is the increase expectations for earnings for 2019, and now that that's finally happened, she's more optimistic about the stocks. The Street now expects biotech's earnings growth will exceed the S&P 500's by 20 basis points, a reversal from the pat two years, when biotechs were expected to lag the index.

  • ETF Trends23 days ago

    Alkermes FDA Refusal: Biotech ETFs Dragged Down

    Biotechnology stocks and biotech ETFs were among the worst performing areas of the markets Monday as Alkermes (NasdaqGS: ALKS) shares plunged after the U.S. food and Drug Administration refused to review ...

  • Market Realist23 days ago

    A New Month for Stocks, but the Same Problems

    A New Month for Stocks, but the Same ProblemsApril coming in like a lion

  • A Look at Ionis’s Key Revenue Drivers in 4Q17
    Market Realistlast month

    A Look at Ionis’s Key Revenue Drivers in 4Q17

    How Ionis Pharmaceuticals Is Positioned in 2018

  • Incyte’s Jakafi in 2017
    Market Realistlast month

    Incyte’s Jakafi in 2017

    Who’s Watching Incyte Corporation in March 2018?

  • The 4 Top Biotech ETFs
    Motley Foollast month

    The 4 Top Biotech ETFs

    Investing in biotechnology has been very lucrative lately, and these funds can help you tap into the industry's success.

  • Here's an ETF to Invest in Immunotherapy--the Game Changing Cancer Treatment
    Zackslast month

    Here's an ETF to Invest in Immunotherapy--the Game Changing Cancer Treatment

    CNCR ETF is up about 30% this year; here is what investors need to know about immunotherapy and the ETF (CNCR, IBB).

  • Investopedialast month

    3 Hot Junior Biotech Plays

    These three small-cap biotech stocks are attracting significant buying interest in this mixed March environment.